Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 2/20 | 0.50 |
| ▸ | CTSK | P43235 | 1/20 | 0.50 |
| ▸ | CTSL | P07711 | 1/20 | 0.49 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | F10 | P00742 | 1/20 | 0.41 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | TACR1 | P25103 | 2/20 | 0.41 |
| ▸ | TACR3 | P29371 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19471121 | 1.00 | CTSS (0.50) | CTSSCTSKCTSLF2F10 | |
| SCHEMBL6184348 | 0.84 | CTSS (0.68) | CTSSCTSKCTSL | |
| SCHEMBL29527373 | 0.82 | CTSS (0.77) | CTSSCTSKCTSL | |
| SCHEMBL17881889 | 0.82 | CTSS (0.77) | CTSSCTSKCTSL | |
| SCHEMBL28652947 | 0.82 | CTSS (0.77) | CTSSCTSKCTSL | |
| SCHEMBL6438579 | 0.80 | CNR1 (0.59) | MEN1KMT2A | |
| SCHEMBL21606787 | 0.79 | NAALAD2 (0.51) | ALDH1A1 | |
| SCHEMBL21606805 | 0.79 | NAALAD2 (0.51) | ALDH1A1 | |
| SCHEMBL21995195 | 0.79 | MEN1 (0.60) | F2F10PRSS1MEN1KMT2A | |
| SCHEMBL4793272 | 0.79 | KMT2A (0.56) | CTSSCTSLF2F10PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4342473-A2 | COMPOUNDS USEFUL IN HIV THERAPY | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2024-03-27 | — | — | EP | disclosed |
| US-20240051972-A1 | Compounds Useful in HIV Therapy | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-02-15 | — | — | US | disclosed |
| US-11873310-B2 | Compounds useful in HIV therapy | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-01-16 | — | — | US | disclosed |
| US-11492361-B2 | Compounds useful in HIV therapy | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-11-08 | — | — | US | disclosed |
| US-20220119417-A1 | Compounds Useful in HIV Therapy | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-04-21 | — | — | US | disclosed |
| EP-3886987-A1 | COMPOUNDS USEFUL IN HIV THERAPY | GlaxoSmithKline Intellectual Property Development Ltd (GB) | 2021-10-06 | — | — | EP | disclosed |
| US-20210009609-A1 | Compounds Useful in HIV Therapy | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-01-14 | — | — | US | disclosed |
| US-10870663-B2 | Compounds useful in HIV therapy | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-12-22 | — | — | US | disclosed |
| US-20200299309-A1 | Compounds Useful in HIV Therapy | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-09-24 | — | — | US | disclosed |
| WO-2020110056-A1 | COMPOUNDS USEFUL IN HIV THERAPY | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119417-A1 | Compounds Useful in HIV Therapy | CD4, CCR5, ABCB1 | CTSS 1451/4885CTSK 2213/4885CTSL 1014/4885 |
| US-20240051972-A1 | Compounds Useful in HIV Therapy | CD4, CCR5, ABCB1 | CTSS 1451/4885CTSK 2213/4885CTSL 1014/4885 |
| US-11873310-B2 | Compounds useful in HIV therapy | CD4, CCR5, ABCB1 | CTSS 1451/4885CTSK 2213/4885CTSL 1014/4885 |
| US-10870663-B2 | Compounds useful in HIV therapy | CCR5, SLC11A2, CD4 | CTSS 1799/4885CTSK 2449/4885CTSL 1431/4885 |
| US-11492361-B2 | Compounds useful in HIV therapy | CD4, CCR5, ABCB1 | CTSS 1287/4885CTSK 2101/4885CTSL 922/4885 |
| US-20200299309-A1 | Compounds Useful in HIV Therapy | CCR5, SLC11A2, CD4 | CTSS 1799/4885CTSK 2449/4885CTSL 1431/4885 |
| US-20210009609-A1 | Compounds Useful in HIV Therapy | CD4, CCR5, ABCB1 | CTSS 1287/4885CTSK 2101/4885CTSL 922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.